endpts.com·Jun 4, 2026
Hikma Pharmaceuticals is investing $267 million in Ohio, which is expected to create 350 new jobs, while Cingulate has received a Complete Response Letter (CRL) for its ADHD drug.
Hikma Pharmaceuticals' $267 million investment in Ohio signals a significant expansion move within the US generic drug market, potentially creating 350 new jobs. This presents a strategic opportunity for stakeholders in healthtech and biotech to explore partnerships or investments in Hikma's expanding operations, particularly in manufacturing and supply chain enhancements.